Abstract
Leptomeningeal metastases (LM), a common problem in neurooncology, occur in approximately 5% of all patients with cancer. Aside from frequent focal signs and symptoms, LM affects the entire neuraxis; therefore, staging and treatment must encompass all cerebrospinal fluid compartments. Central nervous system staging of LM includes contrast-enhanced cranial computed tomography or magnetic resonance imaging, contrast-enhanced spine magnetic resonance imaging or computed tomographic myelography, and radionuclide cerebrospinal fluid flow study. Treatment of LM includes involved-field radiotherapy of bulky or symptomatic disease and intracerebrospinal fluid drug therapy. At present, intracerebrospinal fluid drug therapy is confined to three chemotherapeutic agents (methotrexate, cytosine arabinoside, and thiotepa) and is administered in a variety of schedules by either intralumbar or intraventricular drug delivery. Although treatment of LM is palliative, with an expected median patient survival of 6 months, it often provides stabilization and protection from further neurologic deterioration in patients with LM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
